Addex Therapeutics Ltd ADXN
3.40 USD +0.34 (+11.11%)
Regular-session close
3.33 -0.07 -2.06%
After hours · Nov 19, 4:00 PM ET
3.19 Day range 3.65
2.56 52-week range 10.43
- YTD
- -55.96%
- 1 year
- -62.05%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) stock increased by 62.9% to $0.44 during Thursday's pre-market session. Pulmatrix (NASDAQ:PULM) stock rose 13.58% to $1.52. The company's market cap stands at $4.8…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million. InspireMD (NASDAQ:NSPR) shares…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session. ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their…
benzinga.com Why Tetra Tech Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket Tetra Tech shares jumped 8.5% after beating Q4 estimates; Children's Place surged 302%, while Wheeler REIT fell 35.3% premarket.
globenewswire.com Addex Spin-out Neurosterix Closes $105 Million Series B Financing Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a…
globenewswire.com ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a…
defenseworld.net Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN) Clene (NASDAQ: CLNN - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two…
defenseworld.net Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage What happened Addex Therapeutics Ltd. (NASDAQ: ADXN) said Neurosterix completed Phase 1 studies of NTX-253 and plans to move the drug into Phase 2. NTX-253 is a positive allosteric modulator of the…
globenewswire.com Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a…
globenewswire.com Addex Therapeutics Announces Executive Management Changes Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October…
defenseworld.net What Addex Therapeutics (ADXN) Said on Its Q2 Earnings Call Addex Therapeutics (NASDAQ: ADXN) reported a CHF 1.1 million operating loss for the first half of 2026, compared with CHF 1.3 million a year earlier, as reduced outsourced research and development…
seekingalpha.com Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript
globenewswire.com Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a…
globenewswire.com Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small…
globenewswire.com Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026 Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric…
globenewswire.com ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a…
seekingalpha.com Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript
globenewswire.com Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio…
globenewswire.com Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric…
globenewswire.com Addex Convenes Annual General Meeting 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio…
seekingalpha.com Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript
globenewswire.com Addex Reports Full Year 2025 Financial Results and Provides Corporate Update GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury…
globenewswire.com Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a…
globenewswire.com Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a…
